Efficacy and safety of a lipid-containing artificial tear compared with a non-lipid containing tear: a randomized clinical trial.
Artificial tear
Dry eye
Lipid eye drop
Ocular surface disease
Journal
BMC ophthalmology
ISSN: 1471-2415
Titre abrégé: BMC Ophthalmol
Pays: England
ID NLM: 100967802
Informations de publication
Date de publication:
08 Oct 2024
08 Oct 2024
Historique:
received:
29
03
2024
accepted:
19
09
2024
medline:
9
10
2024
pubmed:
9
10
2024
entrez:
8
10
2024
Statut:
epublish
Résumé
Dry eye disease (DED) is a prevalent condition affecting over 16 million patients in the USA. DED and the symptoms of ocular discomfort are debilitating and a significant burden on patients. If left untreated, DED can progress to cause severe pathology. Treatment is often initiated by patients without consulting a healthcare professional. This study investigated the safety and efficacy of a novel lipid-containing eye drop (BTC), which might better mimic the components of natural tears. This was a multicenter, randomized, double-masked, active control, two arm, parallel group study of eye drops in adult subjects with self-reported DED. Subjects were randomly assigned to BTC or control (commercially available non-lipid eye drops; NLED) arm and were followed for 30 days. Assessments using visual analog scale and patient-reported outcomes (PRO) questionnaires, non-invasive tear break up time, slit-lamp examination, and subject-reported ocular symptoms were conducted at baseline and at days 7 and 30. The primary endpoint was change in overall ocular comfort score from baseline to day 30. 158 subjects were randomized, of whom 130 completed the study per protocol (PP). Mean (SD) age was 47.8 (14.14) years. The mean (95% CI) change in overall comfort scores at the 30-day follow-up in the PP population was 21.4 (15.1, 27.7) for the test drop and 10.0 (3.9, 16.1) for the comparator. The mean (95% CI) treatment difference was 11.3 (2.6, 20.1); this met the pre-defined requirements for non-inferiority. There was no significant difference in the proportion of eyes with reported ocular symptoms between the groups. At day 7, the OR (95% CI) was 0.967 (0.528, 1.770) and at day 30 was 1.160 (0.610, 2.203). There were no Grade 3 or higher corneal edema, corneal neovascularization, corneal staining, conjunctival injection, tarsal abnormalities or any other biomicroscopy findings, and no corneal infiltrates observed during the study. The investigational lipid eye drop BTC was noninferior to the commercially available non-lipid comparator in all parameters measured and has the potential to provide an effective therapy for subjects with symptoms of dry eye who would benefit from a lipid-based artificial tear. NCT03995355 ( http://www. gov ), registered June 24, 2019.
Sections du résumé
BACKGROUND
BACKGROUND
Dry eye disease (DED) is a prevalent condition affecting over 16 million patients in the USA. DED and the symptoms of ocular discomfort are debilitating and a significant burden on patients. If left untreated, DED can progress to cause severe pathology. Treatment is often initiated by patients without consulting a healthcare professional. This study investigated the safety and efficacy of a novel lipid-containing eye drop (BTC), which might better mimic the components of natural tears.
METHODS
METHODS
This was a multicenter, randomized, double-masked, active control, two arm, parallel group study of eye drops in adult subjects with self-reported DED. Subjects were randomly assigned to BTC or control (commercially available non-lipid eye drops; NLED) arm and were followed for 30 days. Assessments using visual analog scale and patient-reported outcomes (PRO) questionnaires, non-invasive tear break up time, slit-lamp examination, and subject-reported ocular symptoms were conducted at baseline and at days 7 and 30. The primary endpoint was change in overall ocular comfort score from baseline to day 30.
RESULTS
RESULTS
158 subjects were randomized, of whom 130 completed the study per protocol (PP). Mean (SD) age was 47.8 (14.14) years. The mean (95% CI) change in overall comfort scores at the 30-day follow-up in the PP population was 21.4 (15.1, 27.7) for the test drop and 10.0 (3.9, 16.1) for the comparator. The mean (95% CI) treatment difference was 11.3 (2.6, 20.1); this met the pre-defined requirements for non-inferiority. There was no significant difference in the proportion of eyes with reported ocular symptoms between the groups. At day 7, the OR (95% CI) was 0.967 (0.528, 1.770) and at day 30 was 1.160 (0.610, 2.203). There were no Grade 3 or higher corneal edema, corneal neovascularization, corneal staining, conjunctival injection, tarsal abnormalities or any other biomicroscopy findings, and no corneal infiltrates observed during the study.
CONCLUSIONS
CONCLUSIONS
The investigational lipid eye drop BTC was noninferior to the commercially available non-lipid comparator in all parameters measured and has the potential to provide an effective therapy for subjects with symptoms of dry eye who would benefit from a lipid-based artificial tear.
TRIAL REGISTRATION
BACKGROUND
NCT03995355 ( http://www.
CLINICALTRIALS
RESULTS
gov ), registered June 24, 2019.
Identifiants
pubmed: 39379885
doi: 10.1186/s12886-024-03688-z
pii: 10.1186/s12886-024-03688-z
doi:
Substances chimiques
Lubricant Eye Drops
0
Lipids
0
Ophthalmic Solutions
0
Banques de données
ClinicalTrials.gov
['NCT03995355']
Types de publication
Journal Article
Randomized Controlled Trial
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
442Informations de copyright
© 2024. The Author(s).
Références
Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, Joo CK, et al. TFOS DEWS II Definition and Classification Report. Ocul Surf. 2017;15(3):276–83.
doi: 10.1016/j.jtos.2017.05.008
pubmed: 28736335
Tsubota K, Pflugfelder SC, Liu Z, Baudouin C, Kim HM, Messmer EM, et al. Defining Dry Eye from a Clinical Perspective. Int J Mol Sci. 20204;21(23):9271.
doi: 10.3390/ijms21239271
pubmed: 33291796
pmcid: 7730816
Lemp MA, Crews LA, Bron AJ, Foulks GN, Sullivan BD. Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. Cornea. 2012;31(5):472–8.
doi: 10.1097/ICO.0b013e318225415a
pubmed: 22378109
Bron AJ, Yokoi N, Gafney E, Tiffany JM. Predicted phenotypes of dry eye: proposed consequences of its natural history. Ocul Surf. 2009;7(2):78–92.
doi: 10.1016/S1542-0124(12)70299-9
pubmed: 19383277
Stapleton F, Alves M, Bunya VY, Jalbert I, Lekhanont K, Malet F, et al. TFOS DEWS II Epidemiology Report. Ocul Surf. 2017;15(3):334–65.
doi: 10.1016/j.jtos.2017.05.003
pubmed: 28736337
Papas EB. The global prevalence of dry eye disease: A Bayesian view. Ophthalmic Physiol Opt. 2021;41(6):1254–66.
doi: 10.1111/opo.12888
pubmed: 34545606
Farrand KF, Fridman M, Stillman IÖ, Schaumberg DA. Prevalence of Diagnosed Dry Eye Disease in the United States Among Adults Aged 18 Years and Older. Am J Ophthalmol. 2017;1(182):90–8.
doi: 10.1016/j.ajo.2017.06.033
Bron AJ, de Paiva CS, Chauhan SK, Bonini S, Gabison EE, Jain S, et al. TFOS DEWS II pathophysiology report. Ocul Surf. 2017;15(3):438–510.
doi: 10.1016/j.jtos.2017.05.011
pubmed: 28736340
Jones L, Downie LE, Korb D, Benitez-Del-Castillo JM, Dana R, Deng SX, et al. TFOS DEWS II Management and Therapy Report. Ocul Surf. 2017;15(3):575–628.
doi: 10.1016/j.jtos.2017.05.006
pubmed: 28736343
Schiffman RM, Walt JG, Jacobsen G, Doyle JJ, Lebovics G, Sumner W. Utility assessment among patients with dry eye disease. Ophthalmology. 2003;110(7):1412–9.
doi: 10.1016/S0161-6420(03)00462-7
pubmed: 12867401
Rolando M, Merayo-Lloves J. Management Strategies for Evaporative Dry Eye Disease and Future Perspective. Curr Eye Res. 2022;47(6):813–23.
doi: 10.1080/02713683.2022.2039205
pubmed: 35521685
Karpecki PM, Nichols KK, Sheppard JD. Addressing Excessive Evaporation: An Unmet Need in Dry Eye Disease. 2023 13 [cited 2024 16]; Available from: https://www.ajmc.com/view/addressing-excessive-evaporation-an-unmet-need-in-dry-eye-disease .
Messmer EM. The pathophysiology, diagnosis, and treatment of dry eye disease. Dtsch Arztebl Int. 2015 30;112(5):71–81; quiz 82.
Mohamed HB, Abd El-Hamid BN, Fathalla D, Fouad EA. Current trends in pharmaceutical treatment of dry eye disease: A review. Eur J Pharm Sci. 2022;1(175):106206.
doi: 10.1016/j.ejps.2022.106206
Baudouin C, Messmer EM, Aragona P, Geerling G, Akova YA, Benítez-del-Castillo J, et al. Revisiting the vicious circle of dry eye disease: a focus on the pathophysiology of meibomian gland dysfunction. Br J Ophthalmol. 2016;100(3):300–6.
doi: 10.1136/bjophthalmol-2015-307415
pubmed: 26781133
Pucker AD, Ng SM, Nichols JJ. Over the counter (OTC) artificial tear drops for dry eye syndrome. Cochrane Database Syst Rev. 2016 23;2(2):CD009729.
Lee SY, Tong L. Lipid-containing lubricants for dry eye: a systematic review. Optom Vis Sci. 2012;89(11):1654–61.
doi: 10.1097/OPX.0b013e31826f32e0
pubmed: 23096494
Garrigue JS, Amrane M, Faure MO, Holopainen JM, Tong L. Relevance of Lipid-Based Products in the Management of Dry Eye Disease. J Ocul Pharmacol Ther. 2017;33(9):647–61.
doi: 10.1089/jop.2017.0052
pubmed: 28956698
pmcid: 5655476
Johnson & Johnson Vision Care, Inc. Clinical Evaluation of an Investigational Lipid Drop in Non-contact Lens Wearing Patients [Internet]. clinicaltrials.gov; 2023 [cited 2023 Jan 1]. Report No.: NCT03995355. Available from: https://clinicaltrials.gov/study/NCT03995355 .
WMA - The World Medical Association-WMA Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects [Internet]. [cited 2023 24]. Available from: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/ .
ISO [Internet]. 2020 [cited 2023 24]. ISO 14155:2020 Clinical investigation of medical devices for human subjects: Good cinical practice. Available from: https://www.iso.org/standard/71690.html .
Labetoulle M, Rolando M, Baudouin C, van Setten G. Patients’ perception of DED and its relation with time to diagnosis and quality of life: an international and multilingual survey. Br J Ophthalmol. 2017;101(8):1100–5.
doi: 10.1136/bjophthalmol-2016-309193
pubmed: 28003235
Bilkhu P, Sivardeen Z, Chen C, Craig JP, Mann K, Wang MTM, et al. Patient-reported experience of dry eye management: An international multicentre survey. Cont Lens Anterior Eye. 2022;45(1).
doi: 10.1016/j.clae.2021.101450
pubmed: 33941501
Nichols KK, Bacharach J, Holland E, Kislan T, Shettle L, Lunacsek O, et al. Impact of Dry Eye Disease on Work Productivity, and Patients’ Satisfaction With Over-the-Counter Dry Eye Treatments. Invest Ophthalmol Vis Sci. 20161;57(7):2975–82.
doi: 10.1167/iovs.16-19419
pubmed: 27273596
Harris Survey Queries Patients with Dry Eye [Internet]. [cited 2024 6]. Available from: http://www.opted.org/files/Volume_37_Number_1_Fall_2011.pdf .
Cwiklik L. Tear film lipid layer: A molecular level view. Biochim Biophys Acta. 2016;1858(10):2421–30.
doi: 10.1016/j.bbamem.2016.02.020
pubmed: 26898663
Baudouin C, Galarreta DJ, Mrukwa-Kominek E, Böhringer D, Maurino V, Guillon M, et al. Clinical evaluation of an oil-based lubricant eyedrop in dry eye patients with lipid deficiency. Eur J Ophthalmol. 201710;27(2):122–8.
doi: 10.5301/ejo.5000883
pubmed: 27791253
Garcia-Lázaro S, Belda-Salmerón L, Ferrer-Blasco T, Cerviño A, Montés-Micó R. Comparison of two artificial tear formulations for dry eye through high-resolution optical coherence tomography. Clin Exp Optom. 2011;94(6):549–56.
doi: 10.1111/j.1444-0938.2011.00632.x
pubmed: 21929716
Chan TCY, Chow SSW, Wan KHN, Yuen HKL. Update on the association between dry eye disease and meibomian gland dysfunction. Hong Kong Med J. 2019;25(1):38–47.
pubmed: 30713149
Goto E, Dogru M, Fukagawa K, Uchino M, Matsumoto Y, Saiki M, et al. Successful tear lipid layer treatment for refractory dry eye in office workers by low-dose lipid application on the full-length eyelid margin. Am J Ophthalmol. 2006;142(2):264–70.
doi: 10.1016/j.ajo.2006.03.022
pubmed: 16876507
Geerling G, Tauber J, Baudouin C, Goto E, Matsumoto Y, O’Brien T, et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction. Invest Ophthalmol Vis Sci. 201130;52(4):2050–64.
doi: 10.1167/iovs.10-6997g
pubmed: 21450919
pmcid: 3072163